The prognostic significance and relationship with body composition of CCR7-positive cells in colorectal cancer

Journal of Surgical Oncology

Volumn 112, Issue 1, 2015, Pages 86-92

  Malietzis, George ^a,b   Lee, Gui Han ^a,b   Bernardo, David ^a   Blakemore, Alexandra I F ^c   Knight, Stella C ^a   Moorghen, Morgan ^b   Al Hassi, Hafid O ^a   Jenkins, John T ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

body composition; CCR7; chemokines; colorectal cancer; immunology; outcomes

Indexed keywords

CHEMOKINE RECEPTOR CCR7; CCR7 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BODY COMPOSITION; CANCER STAGING; CELL DENSITY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LOCAL IMMUNE RESPONSE; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; COLORECTAL NEOPLASMS; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TUMOR INVASION;

AGED; BODY COMPOSITION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CCR7; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84937404089     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23959     Document Type: Article

References (35)

1. Brenner H, Kloor M, Pox CP,: Colorectal cancer. Lancet 2014; 383: 1490-1502.
2. Mantovani A, Allavena P, Sica A,: Cancer-related inflammation. Nature 2008; 454: 436-444.
3. Jass JR,: Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986; 39: 585-589.
4. Richards CH, Roxburgh CS, MacMillan MT, et al.,: The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS ONE 2012; 7: e41883.
5. Roxburgh CS, McMillan DC,: Cancer and systemic inflammation: Treat the tumour and treat the host. Br J Cancer 2014; 110: 1409-1412.
6. Malietzis G, Johns N, Al-Hassi HO, et al.,: Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. Ann Surg 2015 [Epub ahead of print].
7. Wang ZM, Pierson RN, Jr., Heymsfield SB,: The five-level model: A new approach to organizing body-composition research. Am J Clin Nutr 1992; 56: 19-28.
8. Miljkovic I, Zmuda JM,: Epidemiology of myosteatosis. Curr Opin Clin Nutr Metab Care 2010; 13: 260-264.
9. Doyle SL, Bennett AM, Donohoe CL, et al.,: Establishing computed tomography-defined visceral fat area thresholds for use in obesity-related cancer research. Nutr Res 2013; 33: 171-179.
10. Baracos V, Kazemi-Bajestani SM,: Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int J Biochem Cell Biol 2013; 45: 2302-2308.
11. Zlotnik A, Yoshie O,: Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-127.
12. Forster R, Davalos-Misslitz AC, Rot A,: CCR7 and its ligands: Balancing immunity and tolerance. Nat Rev Immunol 2008; 8: 362-371.
13. Grivennikov SI, Greten FR, Karin M,: Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
14. Mei Z, Liu Y, Liu C, et al.,: Tumour-infiltrating inflammation and prognosis in colorectal cancer: Systematic review and meta-analysis. Br J Cancer 2014; 110: 1595-1605.
15. Malietzis G, Aziz O, Bagnall NM, et al.,: The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: A systematic review. Eur J Surg Oncol 2015; 41: 186-196.
16. Klintrup K, Makinen JM, Kauppila S, et al.,: Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005; 41: 2645-2654.
17. Mourtzakis M, Prado CM, Lieffers JR, et al.,: A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metabol 2008; 33: 997-1006.
18. Martin L, Birdsell L, Macdonald N, et al.,: Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-1547.
19. Muller A, Homey B, Soto H, et al.,: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
20. Takeuchi H, Fujimoto A, Tanaka M, et al.,: CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004; 10: 2351-2358.
21. Ding Y, Shimada Y, Maeda M, et al.,: Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 2003; 9: 3406-3412.
22. Takanami I,: Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis. Int J Cancer 2003; 105: 186-189.
23. Mburu YK, Egloff AM, Walker WH, et al.,: Chemokine receptor 7 (CCR7) gene expression is regulated by NF-kappaB and activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck (SCCHN). J Biol Chem 2012; 287: 3581-3590.
24. Gunther K, Leier J, Henning G, et al.,: Prediction of lymph node metastasis in colorectal carcinoma by expressionof chemokine receptor CCR7. Int J Cancer 2005; 116: 726-733.
25. Chuang CW, Pan MR, Hou MF,: Cyclooxygenase-2 up-regulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells. J Cell Physiol 2013; 228: 341-348.
26. Wang D, DuBois RN,: An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J 2013; 19: 502-510.
27. Issa A, Le TX, Shoushtari AN, et al.,: Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res 2009; 69: 349-357.
28. Balkwill FR,: The chemokine system and cancer. J Pathol 2012; 226: 148-157.
29. Schimanski CC, Schwald S, Simiantonaki N, et al.,: Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 2005; 11: 1743-1750.
30. Correale P, Rotundo MS, Botta C, et al.,: Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res 2012; 18: 850-857.
31. Naito Y, Saito K, Shiiba K, et al.,: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58: 3491-3494.
32. Pages F, Kirilovsky A, Mlecnik B, et al.,: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009; 27: 5944-5951.
33. Ling A, Edin S, Wikberg ML, et al.,: The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer 2014; 110: 2551-2559.
34. Vayrynen JP, Tuomisto A, Klintrup K, et al.,: Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer 2013; 109: 1839-1847.
35. Quail DF, Joyce JA,: Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-1437.